2,1,3-苯并噻二唑-4-醇 | 767-66-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 2,1,3-苯并噻二唑-4-醇
• 中文别名: 苯并[C][1,2,5]噻二唑-4(1H)-酮
• 英文名称: benzo[1,2,5]thiadiazol-4-ol
• 英文别名: 4-hydroxybenzo-2,1,3-thiadiazole；4-Hydroxy-2,1,3-benzothiadiazol；4-Hydroxy-benz-2,1,3-thiodiazol；2,1,3-Benzothiadiazol-4-ol
• CAS: 767-66-8
• 化学式: C₆H₄N₂OS
• mdl: MFCD00778455
• 分子量: 152.177
• InChiKey: HYQIDLQSPAWDSE-UHFFFAOYSA-N

物化性质

• 熔点：
  114-115 °C
• 沸点：
  291.1±13.0 °C(Predicted)
• 密度：
  1.554±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2,1,3-苯并噻二唑-4-醇 在 盐酸 、 双氧水 作用下， 以 乙腈 为溶剂， 以41.5%的产率得到5-chloro-4,7-dioxo-4,7-dihydrobenzo-2,1,3-thiadiazole
  参考文献：
  名称：

  4,7-二氧苯并-2,1,3-噻二唑的氯代衍生物的合成与转化

  摘要：

  DOI：

  10.1007/bf00503188
• 作为产物：
  描述：

  4-氨基-2,1,3-苯并噻二唑 在 sodium hydrogensulfite 作用下， 生成 2,1,3-苯并噻二唑-4-醇
  参考文献：
  名称：

  苯并-2,1,3-噻二唑的某些衍生物的氧化和还原

  摘要：

  DOI：

  10.1007/bf00471566

文献信息

• Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
  申请人：Biovitrum AB

  公开号：US06465467B1

  公开（公告）日：2002-10-15

  Compounds of the general formula (I): wherein the variables are as defined in the specification are useful for the prophylaxis or treatment of serotonin-related, especially 5-HT2 receptor-related, diseases in human beings or animals, particularly diseases related to the 5-HT2c receptor, especially diseases such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctionions, and urinary disorders.

  通式（I）的化合物： 其中变量如规范中定义的那样，对于预防或治疗人类或动物中与血清素相关，特别是5-HT2受体相关的疾病是有用的，特别是与5-HT2c受体相关的疾病，尤其是与进食障碍、记忆障碍、精神分裂症、情绪障碍、焦虑障碍、疼痛、性功能障碍和尿液障碍等疾病相关的疾病。
• Synthesis, luminescent and magnetic properties of new tetranuclear lanthanide complexes with 4-hydroxy-2,1,3-benzothiadiazolate and dibenzoylmethanide ligands
  作者：T.S. Sukhikh、D.A. Bashirov、D.S. Kolybalov、A.Y. Andreeva、A.I. Smolentsev、N.V. Kuratieva、V.A. Burilov、A.R. Mustafina、S.G. Kozlova、S.N. Konchenko

  DOI：10.1016/j.poly.2016.12.041

  日期：2017.3

  new tetranuclear complexes, [Ln4(dbm)4(O-btd)6(OH)2] 1a (Ln = Yb), 1b (Ln = Dy) and [Ln4(dbm)6(O-btd)4(OH)2] 2a (Ln = Yb), 2b (Ln = Dy) (O-btd = 4-hydroxo-2,1,3-benzothiadiazolate and dbm = dibenzoylmethanide), and their solvates with toluene and tetrahydrofuran were synthesized. The magnetic properties of the complexes 1a, 1b, 2a and 2b have been studied, revealing different magnetic susceptibility

  摘要四个新的四核配合物[Ln4（dbm）4（O-btd）6（OH）2] 1a（Ln = Yb），1b（Ln = Dy）和[Ln4（dbm）6（O-btd）4（ OH）2] 2a（Ln = Yb），2b（Ln = Dy）（O-btd = 4-羟基-2,1,3-苯并噻二唑酸酯和dbm =二苯甲酰甲烷），并合成了它们与甲苯和四氢呋喃的溶剂化物。研究了配合物1a，1b，2a和2b的磁性，揭示了在80-300 K温度范围内Yb（III）和Dy（III）配合物的磁化率模式不同。两种Yb化合物均观察到反铁磁有序，而Dy衍生物被认为显示弱的铁磁相互作用。Yb络合物1a和2a在激发（O-btd）-配体后，在CH2Cl2溶液中〜1000 nm处显示出很强的NIR发光。
• Monoximes and dioximes of 2,1,3-benzothiadiazole dignes
  作者：A.S. Angeloni、D. Dal Monte、S. Pollicino、E. Sandri、G. Scapini

  DOI：10.1016/s0040-4020(01)97073-5

  日期：1974.1

  4,7-dione. On the basis of NMR data “4 - hydroxy - 5 - nitroso-, 4 - hydroxy - 7 - nitroso- and 5 - hydroxy - 4 - nitroso -2,1,3- benzothiadiazole” exist predominantly in quinonemonoxime forms. Configurations were assigned to geometrical isomers. The 4,5- and 4,7 - di - O - methyidioximinobenzothiadiazoles were also investigated. Four and two geometrical isomers of the 4,5- and 4,7-derivatives, respectively

  对于一系列2,1,3-苯并噻唑-4,5和4,7-二酮的单肟，二肟和单-O-甲基二肟，已经确定了有机溶剂中的NMR光谱和水中的解离常数。根据NMR数据，“ 4-羟基-5-亚硝基，4-羟基-7-亚硝基和5-羟基-4-亚硝基-2,1,3-苯并噻二唑”主要以醌一肟形式存在。将构型分配给几何异构体。还研究了4，5-和4，7-二-O-甲基二氧代二氨基苯并噻二唑。4,5和4,7衍生物的四个和两个几何异构体已被分离，并描述了每种异构体的物理和光谱性质。
• 4-Hydroxy-2,1,3-benzthiadiazole compounds and .beta.-adrenergic method
  申请人：Boehringer Mannheim GmbH

  公开号：US04436742A1

  公开（公告）日：1984-03-13

  New amine derivatives of 4-hydroxy-2,1,3-benzthiadiazoles of the formula: ##STR1## wherein R is straight-chained or branched alkyl and the pharmacologically compatible salts thereof, that are markedly effected as inhibitors of adrenogenic .beta.-receptors and thus useful for the treatment and prophylaxis of cardiac and circulatory diseases.

  4-羟基-2,1,3-苯并噻二唑的新氨基衍生物的化学式为：##STR1## 其中R是直链或支链烷基，以及与药理学相容的盐。这些衍生物是明显的肾上腺素能β受体抑制剂，因此可用于治疗和预防心脏和循环系统疾病。
• Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
  申请人：Biovitrum, AB, a Stockholm, Sweden corporation

  公开号：US20030092694A1

  公开（公告）日：2003-05-15

  The invention relates to compounds of the general formula (I): 1 wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO 2 —, —NH—, (ii) a C 1-4 -alkyl- or C 1-6 -acyl-substituted nitrogen atom or (iii) a C 1-8 -alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R 4 )(R 5 )—, —OC(R 4 )(R 5 )—, —N(R 6 )C(R 4 )(R 5 )—, —N(R 6 )—, —O—, —S— or —SO 2 —; R is optionally substituted C 3-8 -cycloalkyl, aryl or heteroaryl; R 1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R 4 )(R 5 )] x N(R 2a )(R 3a )]; R 2a , R 3a , R 4 , R 5 , R 6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I)

  本发明涉及一般式（I）的化合物：其中Ar是可选取代的芳基或杂环芳基；A是（i）-O-，-S-，-SO2-，-NH-，（ii）C1-4-烷基或C1-6-酰基取代的氮原子或（iii）C1-8-烷基链或具有2至8个链原子的杂烷基链，可选地含有至少一个不饱和度，并且可以取代和/或包含桥以形成具有3-8个环成员的饱和或部分或完全不饱和的环；B是-C（R4）（R5）-，-OC（R4）（R5）-，-N（R6）C（R4）（R5）-，-N（R6）-，-O-，-S-或-SO2-；R是可选取代的C3-8-环烷基，芳基或杂环芳基；R1是（i）饱和或不饱和的氮杂环或氨基氮杂环环，或具有4至7个环成员的饱和二氮杂环或氨基二氮杂环环，或具有7至10个环成员的饱和氨基氮杂双环、氮杂双环或二氮杂双环环，这些环可选地在一个或多个位置上取代，或一个组-［C（R4）（R5）］xN（R2a）（R3a）；其中R2a，R3a，R4，R5，R6和x如所述，n为0或1；以及其药学上可接受的盐、水合物和前药形式。这些化合物可以通过常规方法制备，并可用于治疗患有血清素相关疾病的人类或动物受试者，例如进食障碍，特别是肥胖，记忆障碍，精神分裂症，情绪障碍，焦虑症，疼痛，性功能障碍和泌尿系统疾病。本发明还涉及这种用途以及包含式（I）化合物的药物组合物。